Dr. Paul Lammers President & Chief Executive Officer Triumvira Immunologics www.triumvira.com Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – March 4, 2019 CEOCFO: Dr. Lammers, you have been president and CEO for a little...
MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative...
AUSTIN, Texas, and HAMILTON, Ontario, January 29, 2019 – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that Dr. Paul Lammers, President & CEO, will...
AUSTIN, Texas & HAMILTON, Ontario & TORONTO – AUSTIN, Texas, and HAMILTON, Ontario, January 23, 2019 – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today...
AUSTIN, Texas & HAMILTON, Ontario & TORONTO – Triumvira Immunologics Inc., announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week for healthcare investors at the Hilton San Francisco Union Square. Paul...
AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), announced the presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, held December...
